CY1116075T1 - Νεες συνθεσεις λιποσωματων - Google Patents

Νεες συνθεσεις λιποσωματων

Info

Publication number
CY1116075T1
CY1116075T1 CY20151100123T CY151100123T CY1116075T1 CY 1116075 T1 CY1116075 T1 CY 1116075T1 CY 20151100123 T CY20151100123 T CY 20151100123T CY 151100123 T CY151100123 T CY 151100123T CY 1116075 T1 CY1116075 T1 CY 1116075T1
Authority
CY
Cyprus
Prior art keywords
liposome compositions
new liposome
containing compositions
lipid
targeted liposomes
Prior art date
Application number
CY20151100123T
Other languages
English (en)
Inventor
Kazushi Okada
Tadayuki Ibuki
Donghyun Kim
Tadashi Fujisawa
Original Assignee
Mebiopharm Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mebiopharm Co., Ltd. filed Critical Mebiopharm Co., Ltd.
Publication of CY1116075T1 publication Critical patent/CY1116075T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα περιγραφή παρέχει συνθέσεις που περιέχουν λιπίδια, συμπεριλαμβανομένων στοχευόμενων λιποσωμάτων που ενκαψουλιώνουν φάρμακο, και φαρμακευτικών σκευασμάτων αυτών, όπως επίσης και μεθόδους για την παρασκευή και χρήση των συνθέσεων που περιέχουν λιπίδια, συμπεριλαμβανομένης της χρήσης των στοχευόμενων λιποσωμάτων για τη θεραπεία του καρκίνου κι άλλων ασθενειών.
CY20151100123T 2005-03-10 2015-02-06 Νεες συνθεσεις λιποσωματων CY1116075T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005067469A JP2006248978A (ja) 2005-03-10 2005-03-10 新規なリポソーム製剤
EP06737793.7A EP1863448B1 (en) 2005-03-10 2006-03-08 Novel liposome compositions

Publications (1)

Publication Number Publication Date
CY1116075T1 true CY1116075T1 (el) 2017-02-08

Family

ID=36992280

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100123T CY1116075T1 (el) 2005-03-10 2015-02-06 Νεες συνθεσεις λιποσωματων

Country Status (22)

Country Link
US (3) US7829113B2 (el)
EP (1) EP1863448B1 (el)
JP (2) JP2006248978A (el)
KR (1) KR101352490B1 (el)
CN (1) CN101170995B (el)
AU (1) AU2006223329B2 (el)
BR (1) BRPI0608297A2 (el)
CA (1) CA2600446A1 (el)
CY (1) CY1116075T1 (el)
DK (1) DK1863448T3 (el)
ES (1) ES2529453T3 (el)
HK (1) HK1111625A1 (el)
HU (1) HUE024290T2 (el)
MX (1) MX2007010996A (el)
NO (1) NO20075136L (el)
NZ (1) NZ561569A (el)
PL (1) PL1863448T3 (el)
PT (1) PT1863448E (el)
RU (1) RU2454229C2 (el)
SI (1) SI1863448T1 (el)
WO (1) WO2006099169A2 (el)
ZA (1) ZA200708600B (el)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1980637B (zh) 2004-05-03 2014-02-19 赫尔姆生物科学公司 用于药物输送的脂质体
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
CN101209243B (zh) * 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
ES2550759T3 (es) * 2007-08-17 2015-11-12 Celator Pharmaceuticals, Inc. Formulaciones farmacológicas de platino mejoradas
SI2194987T1 (sl) 2007-09-10 2016-10-28 Boston Biomedical, Inc. Novi inhibitorji poti stat3 in inhibitorji matičnih celic raka
TWI468188B (zh) 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
BR112012000826B1 (pt) * 2009-07-06 2022-07-26 Variation Biotechnologies Inc Método para a preparação de vesículas
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
WO2011038068A1 (en) * 2009-09-23 2011-03-31 Formatech, Inc. Methods for the preparation of liposomes
US10143652B2 (en) * 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
WO2011102904A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion therapeutic delivery system
SI2547205T1 (sl) 2010-03-19 2024-08-30 1Globe Biomedical Co., Ltd. Novi postopki za ciljanje rakastih matičnih celic
WO2011128896A1 (en) * 2010-04-12 2011-10-20 Ramot At Tel-Aviv University Ltd. Iron oxide nanoparticles for use in treating non-infectious inflammatory disorders
KR101819688B1 (ko) 2010-11-12 2018-01-17 코어 파마슈티칼스 디벨롭먼트 컴퍼니 변형된 면역-조절 입자
WO2012153616A1 (ja) * 2011-05-10 2012-11-15 国立大学法人北海道大学 標的細胞移行能を有する脂質膜構造体、その製造方法および標的細胞において効果を示す物質のスクリーニング方法
US20140161876A1 (en) * 2011-07-15 2014-06-12 Konica Minolta, Inc. Liposome-containing preparation utilizing dissolution aid, and method for producing same
EP3613852A3 (en) 2011-07-22 2020-04-22 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
US20150216998A1 (en) * 2012-01-01 2015-08-06 Ramot At Tel-Aviv University Ltd. Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
WO2013192532A2 (en) 2012-06-21 2013-12-27 Northwestern University Peptide conjugated particles
WO2014025042A1 (ja) 2012-08-10 2014-02-13 大鵬薬品工業株式会社 安定なオキサリプラチン封入リポソーム水分散液及びその安定化方法
WO2014092858A1 (en) * 2012-12-12 2014-06-19 Temple University - Of The Commonwealth System Of Higher Education Compositions and methods for treatment of cancer
CN103083239B (zh) * 2012-12-26 2015-11-25 中国人民解放军第四军医大学 一种蟾毒灵脂质体及其制备方法和应用
TW201427681A (zh) 2013-01-07 2014-07-16 Superlab Far East Ltd 用空間構象改變的重組干擾素治療腫瘤的方法
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
WO2014159760A1 (en) * 2013-03-13 2014-10-02 Mallinckrodt Llc Liposome oxaliplatin compositions for cancer therapy
MX2015011434A (es) 2013-03-13 2016-08-03 Cour Pharmaceuticals Dev Company Partículas inmunomodificadoras para el tratamiento de la inflamación.
EP2968142A1 (en) * 2013-03-13 2016-01-20 Mallinckrodt LLC Liposomal cisplatin compositions for cancer therapy
AU2014250940A1 (en) 2013-04-09 2015-10-22 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
DK3033102T4 (da) 2013-08-13 2024-02-26 Univ Northwestern Peptidkonjugerede partikler
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
WO2016070129A1 (en) 2014-10-30 2016-05-06 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
KR102523466B1 (ko) 2013-11-07 2023-04-20 에디타스 메디신, 인코포레이티드 지배적인 gRNA를 이용하는 CRISPR-관련 방법 및 조성물
US9068179B1 (en) 2013-12-12 2015-06-30 President And Fellows Of Harvard College Methods for correcting presenilin point mutations
US20170007700A1 (en) * 2014-02-21 2017-01-12 The Curators Of The University Of Missouri Compositions and methods for boron neutron capture therapy
CA2956224A1 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US10098813B2 (en) * 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
WO2016208481A1 (ja) 2015-06-24 2016-12-29 日本化薬株式会社 新規白金（ｉｖ）錯体
KR20180037210A (ko) 2015-08-20 2018-04-11 입센 바이오팜 리미티드 암 치료를 위한 리포좀 이리노테칸 및 parp 저해제를 이용하는 조합요법
WO2017034957A1 (en) 2015-08-21 2017-03-02 Merrimack Pharmaceuticals, Inc. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
BR112018003530A2 (pt) 2015-09-14 2018-09-25 Nippon Kayaku Kabushiki Kaisha conjugado de polímero de complexo de platina hexacoordenado
SG10201912568PA (en) 2015-10-16 2020-02-27 Ipsen Biopharm Ltd Stabilizing camptothecin pharmaceutical compositions
AU2016342380B2 (en) 2015-10-23 2022-04-07 President And Fellows Of Harvard College Nucleobase editors and uses thereof
WO2017087685A1 (en) * 2015-11-20 2017-05-26 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
EP3395857B1 (en) 2015-12-22 2021-05-26 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of sulfoxide derivative-coordinated platinum(ii) complex
CN110590855B (zh) 2016-01-25 2023-05-12 沈阳药科大学 铂类配合物的制备方法及其含有该铂类配合物的脂质体与制备方法
CN109312341B (zh) 2016-03-07 2024-02-27 美国政府(由卫生和人类服务部的部长所代表) 微小rna及其使用方法
CN109069817B (zh) * 2016-04-15 2021-07-13 富士胶片株式会社 微针阵列
EP3493790A4 (en) * 2016-08-02 2020-03-25 Curirx Inc. LIPOSOME PREPARATION METHODS
GB2568182A (en) 2016-08-03 2019-05-08 Harvard College Adenosine nucleobase editors and uses thereof
JP7201153B2 (ja) 2016-08-09 2023-01-10 プレジデント アンド フェローズ オブ ハーバード カレッジ プログラム可能ｃａｓ９－リコンビナーゼ融合タンパク質およびその使用
CA3033077C (en) 2016-08-12 2024-06-18 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
SG11201903089RA (en) 2016-10-14 2019-05-30 Harvard College Aav delivery of nucleobase editors
MA46709A (fr) 2016-11-02 2019-09-11 Ipsen Biopharm Ltd Traitement du cancer gastrique au moyen de polythérapies comprenant de l'oxaliplatine, du 5-fluoruracile (et de la leucovorine) et de l'irinotécan sous forme liposomale
EP3538546A1 (en) 2016-11-14 2019-09-18 Novartis AG Compositions, methods, and therapeutic uses related to fusogenic protein minion
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
CA3057192A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
WO2018209342A1 (en) * 2017-05-12 2018-11-15 Curinanorx, Llc Methods for the preparation of liposomes comprising drugs
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
US12076402B2 (en) 2018-02-07 2024-09-03 L.E.A.F. Holdings Group Llc Alpha polyglutamated antifolates and uses thereof
WO2019157129A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
CN111954531A (zh) 2018-02-07 2020-11-17 L.E.A.F.控股集团公司 α聚谷氨酸化培美曲塞及其用途
US12048767B2 (en) 2018-02-14 2024-07-30 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof
WO2019160734A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
CA3090992A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof
WO2019200043A1 (en) * 2018-04-11 2019-10-17 New Mexico Tech University Research Park Coporation Lipid prodrugs for use in drug delivery
CN108524450A (zh) * 2018-04-16 2018-09-14 温州医科大学 基于磁性热敏阳离子脂质体的奥沙利铂和mdc1-as共传递药物载体的制备及应用
EP3806887A4 (en) 2018-06-13 2022-04-06 California Institute of Technology NANOPARTICLES FOR CROSSING THE BLOOD-BRAIN BARRIER AND METHODS OF TREATMENT USING IT
KR20210068485A (ko) 2018-09-28 2021-06-09 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 노화를 역전시키고 기관 및 조직 재생을 촉진시키기 위한 세포 재프로그래밍
AU2019359299B2 (en) 2018-10-09 2022-04-21 The University Of British Columbia Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto
SG11202109679VA (en) 2019-03-19 2021-10-28 Broad Inst Inc Methods and compositions for editing nucleotide sequences
CN111721841B (zh) * 2019-03-19 2022-07-12 海南长安国际制药有限公司 与洛铂有关物质的检测
CN110292563B (zh) * 2019-06-12 2021-07-16 兰州大学 基于叶酸热敏脂质体的阴离子载体诱导癌细胞凋亡的方法
JP2023516379A (ja) * 2020-03-04 2023-04-19 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド 修飾リポソームを使用する組成物および方法
MX2022012265A (es) 2020-04-02 2023-01-11 Mirecule Inc Inhibicion dirigida utilizando oligonucleotidos ingenieria.
MX2022014008A (es) 2020-05-08 2023-02-09 Broad Inst Inc Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo.
CN112129871B (zh) * 2020-09-04 2021-06-15 斯微(上海)生物科技有限公司 复合磷脂脂质体中dope和m5两种磷脂含量的检测方法
CN112870164B (zh) * 2021-01-25 2021-12-17 山东大学 一种双靶向载药脂质体及其制备方法和应用
WO2023196851A1 (en) 2022-04-06 2023-10-12 President And Fellows Of Harvard College Reversing aging of the central nervous system

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
GR75598B (el) 1980-04-29 1984-08-01 Sanofi Sa
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4565696A (en) 1983-08-03 1986-01-21 The Regents Of The University Of California Production of immunogens by antigen conjugation to liposomes
US4789633A (en) 1984-04-19 1988-12-06 University Of Tennessee Research Corporation Fused liposome and acid induced method for liposome fusion
US4925661A (en) 1984-04-19 1990-05-15 Leaf Huang Target-specific cytotoxic liposomes
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
WO1986004232A1 (en) * 1985-01-18 1986-07-31 Cooper-Lipotech, Inc. Liposome composition and method
US4762915A (en) * 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
US5026651A (en) 1985-04-25 1991-06-25 Board Of Regents, The University Of Texas System Methods and compositions for the production of human transferrin
PH26160A (en) * 1985-08-19 1992-03-18 Univ Texas Pharmaceutical compositions consisting of acylated phospholipids
US4983397A (en) 1985-08-19 1991-01-08 Board Of Regents, University Of Texas System Pharmaceutical compositions consisting of acylated phospholipids
US5384127A (en) 1985-10-18 1995-01-24 Board Of Regents, The University Of Texas System Stable liposomal formulations of lipophilic platinum compounds
JPH0714865B2 (ja) 1986-10-28 1995-02-22 武田薬品工業株式会社 リポソ−ム製剤およびその製造法
US5049390A (en) 1987-09-02 1991-09-17 Allergy Immuno Technologies, Inc. Liposome containing immunotherapy agents for treating IgE mediated allergies
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
FR2631826B1 (fr) 1988-05-27 1992-06-19 Centre Nat Rech Scient Vecteur particulaire utile notamment pour le transport de molecules a activite biologique et procede pour sa preparation
JPH0720857B2 (ja) 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
DE69034042T2 (de) 1989-08-02 2003-07-17 Mitra Medical Technology Ab, Lund System zur verwendung in einem verfahren zur therapeutischen und diagnostischen behandlung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ATE119767T1 (de) * 1990-10-09 1995-04-15 Vestar Inc Vesikel aus phospholipidderivaten mit einem succinimidylsubstituenten.
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US6509032B1 (en) 1991-08-28 2003-01-21 Mcmaster University Cationic amphiphiles
US5292524A (en) 1991-09-06 1994-03-08 California Institute Of Technology Blood platelet loaded with diagnostic or therapeutic-containing liposome or reconstituted Sendai virus
JPH0776230B2 (ja) 1992-01-13 1995-08-16 田中貴金属工業株式会社 白金化合物の製造方法
JPH06287021A (ja) 1992-04-22 1994-10-11 Tanaka Kikinzoku Kogyo Kk 光学活性な白金錯化合物の光学的分割方法
JP2673331B2 (ja) 1993-01-12 1997-11-05 田中貴金属工業 株式会社 光学的に高純度なシス―オキザラート（トランス―１―１，２―シクロヘキサンジアミン）白金（▲ｉｉ▼）
US20030190638A1 (en) 1992-05-13 2003-10-09 Board Of Regents, The University Of Texas System Methods of screening for compounds that derepress or increase telomerase activity
US20030100489A1 (en) 1992-10-16 2003-05-29 Beach David H. Cell-cycle regulatory proteins, and uses related thereto
US5962316A (en) 1992-10-16 1999-10-05 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
AU6833994A (en) 1993-05-17 1994-12-12 Liposome Company, Inc., The Incorporation of taxol into liposomes and gels
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
US5534241A (en) 1993-07-23 1996-07-09 Torchilin; Vladimir P. Amphipathic polychelating compounds and methods of use
DK0671905T3 (da) * 1993-10-06 2002-10-07 Amgen Inc Stabile protein:pholipidsammensætninger samt fremgangsmåder
US6087171A (en) 1993-12-17 2000-07-11 Spinal Cord Society Method for inducing DNA synthesis in neurons
US6057299A (en) 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
JP3590983B2 (ja) * 1994-03-04 2004-11-17 日本油脂株式会社 リン脂質誘導体
CA2185810A1 (en) 1994-03-28 1995-10-05 Jo Klaveness Liposomes
DK0773921T3 (da) 1994-07-29 2000-05-08 Abbott Lab Fremgangsmåde til fremstilling af en substitueret 2,5-diamino-3-hydroxyhexan
US5716988A (en) 1994-08-08 1998-02-10 Debiopharm S.A. Pharmaceutically stable preparation of oxaliplatinum
DE69519802T2 (de) * 1994-10-14 2001-04-19 The Liposome Co.,Inc. Etherlipid-liposomen und deren therapeutische verwendung
ES2206478T3 (es) 1994-11-11 2004-05-16 Debiopharm S.A. Composiciones carcinostaticas que contienen cis-oxaliplatino y otra u otras sustancias carcinostaticas compatibles.
US5786214A (en) 1994-12-15 1998-07-28 Spinal Cord Society pH-sensitive immunoliposomes and method of gene delivery to the mammalian central nervous system
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
US6008202A (en) 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
TW319763B (el) 1995-02-01 1997-11-11 Epix Medical Inc
US5780052A (en) 1995-04-24 1998-07-14 Northeastern University Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell
US5834012A (en) 1995-05-03 1998-11-10 Roman Perez-Soler Lipid complexed topoisomerase I inhibitors
US20020022264A1 (en) 1995-05-26 2002-02-21 Sullivan Sean M. Delivery vehicles comprising stable lipid/nucleic acid complexes
US6825174B2 (en) 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
JPH09278785A (ja) 1996-04-10 1997-10-28 Tanaka Kikinzoku Kogyo Kk 白金化合物の製造方法
FR2740686B1 (fr) 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
US6428977B1 (en) 1995-12-20 2002-08-06 Curis, Inc. Signalin family of TGFβ signal transduction proteins, and uses related thereto
JP3735921B2 (ja) 1996-02-07 2006-01-18 三菱ウェルファーマ株式会社 ＧＰＩｂ・脂質複合体およびその用途
AU2112697A (en) 1996-02-09 1997-08-28 Pi-Wan Cheng Receptor ligand-facilitated delivery of biologically active molecules
EP0897389B1 (fr) 1996-03-11 2002-07-03 Yoshinori Kidani Complexes de platine dinucleaires, procede pour leur preparation et compositions pharmaceutiques en contenant
WO1997035560A1 (en) 1996-03-28 1997-10-02 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved echogenic liposome compositions
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
US6228391B1 (en) 1996-05-02 2001-05-08 Terumo Kabushiki Kaisha Amidine derivatives and drug carriers comprising the same
WO1998007409A1 (en) 1996-08-23 1998-02-26 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
CA2276269C (en) 1996-10-15 2008-09-02 The Liposome Company, Inc. N-acyl phosphatidylethanolamine-mediated liposomal drug delivery
DE69723473T2 (de) * 1996-10-15 2004-05-27 The Liposome Co., Inc. Peptid-lipid konjugate, liposomen und liposomale arzneimittelverabreichung
WO1998027209A1 (en) 1996-12-18 1998-06-25 Emory University Polycationic oligomers
DK1014990T3 (da) 1997-03-07 2006-12-11 Sanofi Aventis Us Llc Antitumorkombination af 3 amino-1,2,4 benzotriazin-1,4 dioxid/paclitaxel/platin
JPH10253632A (ja) 1997-03-10 1998-09-25 Nissui Pharm Co Ltd 分析方法、キット及び装置
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6524613B1 (en) 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
US6272370B1 (en) 1998-08-07 2001-08-07 The Regents Of University Of Minnesota MR-visible medical device for neurological interventions using nonlinear magnetic stereotaxis and a method imaging
WO1998059035A2 (en) 1997-06-25 1998-12-30 The Goverment Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services, National Institutes Of Health Serum-free cell growth medium
EP1007564A4 (en) 1997-07-15 2002-09-18 Univ California ISOLATED DNA ENCODING A HUMAN POTASSIUM-ACTIVATED POTASSIUM CHANNEL
EP1002103B1 (en) 1997-08-04 2007-10-17 Cell Genesys, Inc. A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
KR20010030854A (ko) 1997-10-02 2001-04-16 로퍼, 랜달 비. 인터벤셔날 요법을 모니터하기 위한 콘트라스트 강화된진단 영상화 방법
US6749863B1 (en) 1997-11-19 2004-06-15 Georgetown University Targeted liposome gene delivery
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
US6573101B1 (en) 1998-02-12 2003-06-03 The Regents Of The University Of California Compositions for receptor/liposome mediated transfection and methods of using same
GB9804013D0 (en) 1998-02-25 1998-04-22 Sanofi Sa Formulations
US6245427B1 (en) 1998-07-06 2001-06-12 DüZGüNES NEJAT Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles
ES2178474T3 (es) 1998-10-14 2002-12-16 Debiopharm Sa Acondicionamiento de una preparacion de oxaliplatino.
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
WO2000069915A2 (en) 1999-05-17 2000-11-23 Avi Biopharma, Inc. COMBINED APPROACH TO TREATMENT OF CANCER WITH hCG VACCINES
JP2001002592A (ja) 1999-06-18 2001-01-09 Dai Ichi Seiyaku Co Ltd 遺伝子導入用組成物
US6280054B1 (en) * 1999-07-02 2001-08-28 Zight Corporation Image generator having an improved illumination system
US6242188B1 (en) 1999-07-30 2001-06-05 Applied Gene Technologies, Inc. Sample processing to release nucleic acids for direct detection
WO2001011826A1 (fr) * 1999-08-09 2001-02-15 Fujitsu Limited Dispositif et technique de commande de paquets
ES2206288T3 (es) 1999-08-30 2004-05-16 Debiopharm S.A. Preparacion farmaceutica estable de oxiliplatino para su administracion por via parenteral.
IL150484A0 (en) 1999-12-30 2002-12-01 Novartis Ag Novel colloid synthetic vectors for gene therapy
BR0016864A (pt) 1999-12-30 2002-09-24 Judith K Gwathmey Sistema de fornecimento de quelante de ferro, e, métodos de preparação de um sistema de fornecimento de quelante de ferro e de tratamento de sobrecarga de ferro em um mamìfero em necessidade de tratamento
EP1471870B1 (en) * 2000-01-10 2014-08-20 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Use of lipid conjugates in the treatment of disease
US6530944B2 (en) 2000-02-08 2003-03-11 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US7001735B2 (en) 2000-03-01 2006-02-21 Albert Einstein College Of Medicine Of Yeshiva University Glucose transporter/sensor protein and uses thereof
ATE374785T1 (de) 2000-03-02 2007-10-15 Mitsubishi Pharma Corp Gpib-gebundenes konstrukt und verwendungen davon
JP4449147B2 (ja) 2000-03-22 2010-04-14 日油株式会社 ホスファチジルエタノールアミン誘導体の製造方法
FR2806727A1 (fr) 2000-03-23 2001-09-28 Pf Medicament Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
EP1272160B1 (en) 2000-04-12 2007-01-17 Liplasome Pharma A/S Lipid-based drug delivery systems for topical application
HUP0301835A2 (hu) 2000-05-03 2003-09-29 Mbt Munich Biotechnology Ag Kationos diagnosztikai, képalkotó és terápiás ágensek, aktivált vaszkuláris helyekkel asszociálódva
US20030059461A1 (en) 2000-06-06 2003-03-27 Sibtech, Inc. Molecular delivery vehicle for delivery of selected compounds to targets
US20030072794A1 (en) 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
DE60136747D1 (de) 2000-09-11 2009-01-08 Pasteur Institut Mitochondrialen membrane permeabilisierung durch hiv-1 vpr und screeningsverfahren
US20040234588A1 (en) 2000-09-21 2004-11-25 University Of Georgia Research Foundation, Inc. Artificial lipoprotein carrier system for bioactive materials
DE60108405D1 (de) 2000-10-03 2005-02-17 Debiopharm Sa Plga/pla-typ mikrokugeln enthaltend eine wasserlösliche verbindung und herstellungsverfahren dafür
US20030129223A1 (en) 2000-10-11 2003-07-10 Targesome, Inc. Targeted multivalent macromolecules
AU2002231637A1 (en) 2000-11-22 2002-06-03 Vectron Therapeutics Ag Production and use of a targeted diagnostic system
WO2002048671A1 (en) 2000-12-12 2002-06-20 Australian Institute Of Marine Science Assay for paralytic shellfish toxin
AU2002223013A1 (en) * 2000-12-12 2002-06-24 Debiopharm S.A. Pharmaceutical oxaliplatinum preparation for parenteral administration and method for obtaining same
US6897196B1 (en) 2001-02-07 2005-05-24 The Regents Of The University Of California pH sensitive lipids based on ortho ester linkers, composition and method
US6703524B2 (en) 2001-02-20 2004-03-09 Lkt Laboratories, Inc. Organoselenium compounds for cancer chemoprevention
DE60220766T2 (de) 2001-03-02 2008-03-06 Debiopharm S.A. Verwendung eines eine oxaliplatinlösung beinhaltenden fläschchens
FI113840B (fi) 2001-03-26 2004-06-30 Ctt Cancer Targeting Tech Oy Matriisi-metalloproteinaasi-inhibiittorien käyttö liposomien kohdentamisessa
US20040049022A1 (en) 2001-04-24 2004-03-11 Nyce Jonathan W. Composition & methods for treatment and screening
AU2002256398A2 (en) 2001-04-30 2002-11-11 Targeted Genetics Corporation Lipid-comprising drug delivery complexes and methods for their production
US20030082228A1 (en) 2001-05-09 2003-05-01 Inex Pharmaceuticals Corporation Anti-angiogenic therapy using liposome-encapsulated chemotherapeutic agents
US20030108986A1 (en) 2001-06-21 2003-06-12 Euroscreen, S.A. Compositions and methods comprising G-protein coupled receptors
US20040186172A1 (en) 2001-07-02 2004-09-23 Houssam Ibrahim Oxaliplatin active substance with a very low content of oxalic acid
US20030096299A1 (en) 2001-07-09 2003-05-22 Valerie Wittamer Natural ligand of G protein coupled receptor ChemR23 and uses thereof
CA2457148A1 (en) 2001-08-20 2003-02-27 Transave, Inc. Treatment of cancers by inhalation of stable platinum-containing formulations
DE10144252A1 (de) 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
WO2003028640A2 (en) 2001-10-03 2003-04-10 Vanderbilt University In vivo panning for ligands to radiation-induced molecules
AU2002346446A1 (en) 2001-11-20 2003-06-10 Baylor College Of Medicine Methods and compositions in checkpoint signaling
JP4468617B2 (ja) 2001-12-04 2010-05-26 デビオファーム エス．アー． 抗癌剤の併用投与方法及び併用可能な抗癌剤
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
JP4360915B2 (ja) 2002-01-07 2009-11-11 ユーロスクリーン・ソシエテ・アノニム Ｇタンパク質共役受容体ｇｐｒ４３のリガンドおよびその使用
US20030220284A1 (en) 2002-02-22 2003-11-27 Patricia Yotnda Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
DK1483294T3 (da) 2002-03-01 2010-11-08 Immunomedics Inc Internaliserende anti-CD74-antistoffer og fremgangsmåder til deres anvendelse
EP1587944A4 (en) 2002-03-01 2007-03-21 Dyax Corp KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
WO2003082907A1 (en) 2002-03-29 2003-10-09 Euroscreen Sa Ligands for g protein coupled receptor gpr7 and uses thereof
CA2391438A1 (en) 2002-05-01 2003-11-01 Procyon Biopharma Inc. Psp94 diagnostic reagents and assays
US20030228285A1 (en) 2002-05-03 2003-12-11 Mien-Chie Hung Bipartite T-cell factor (Tcf)-responsive promoter
US7460960B2 (en) 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
JP3415131B1 (ja) 2002-06-03 2003-06-09 メビオファーム株式会社 リポソーム製剤
FR2840236B1 (fr) 2002-06-03 2005-02-04 Inst Francais Du Petrole Membrane zeolithique de faible epaisseur, sa preparation et son utilisation en separation
US20040022842A1 (en) 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
EP1511518A2 (en) 2002-06-07 2005-03-09 Immunomedics, Inc. Neutrophil imaging methods in cystic fibrosis
CA2489469C (en) 2002-06-14 2016-03-22 Immunomedics, Inc. Monoclonal antibody pam4 and its use for diagnosis and therapy of pancreatic cancer
ES2524767T3 (es) 2002-06-14 2014-12-12 Immunomedics, Inc. Anticuerpo monoclonal humanizado HPAM4
US6790632B2 (en) 2002-06-17 2004-09-14 Stephen Eliot Zweig Membrane receptor reagent and assay
AU2003245160B2 (en) 2002-06-28 2009-09-24 Arbutus Biopharma Corporation Method and apparatus for producing liposomes
AU2003248982B2 (en) 2002-08-01 2009-12-10 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
US20040132652A1 (en) 2002-08-30 2004-07-08 Shire Biochem Inc. Pharmaceutical compositions
WO2004045519A2 (en) 2002-11-14 2004-06-03 Kirk Sperber Induction of apoptosis by hiv-1 infected monocytic cells
US20060141019A1 (en) 2002-11-15 2006-06-29 Toshiya Kai Liposome
CA2511623A1 (en) 2003-02-17 2004-08-26 Mebiopharm Co., Ltd. Remedy for cancer
JP2006526408A (ja) 2003-04-22 2006-11-24 アイビーシー、ファーマシューティカルズ 多価タンパク質複合体
AU2004268932B2 (en) 2003-06-13 2010-06-24 Immunomedics, Inc. D-amino acid peptides
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
JP2005154282A (ja) 2003-11-20 2005-06-16 Mebiopharm Co Ltd ガス封入リポソームの製造法
US7582430B2 (en) * 2004-01-20 2009-09-01 United States Of America As Represented By The Secretary Of The Army Immunoliposome-nucleic acid amplification (ILNAA) assay
US7212869B2 (en) * 2004-02-04 2007-05-01 Medtronic, Inc. Lead retention means
CN1679957B (zh) 2004-03-15 2010-06-09 尼普洛株式会社 含脂质体的癌症治疗用药物组合物
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
WO2008030818A2 (en) 2006-09-05 2008-03-13 Mebiopharm Co., Ltd. Novel liposome compositions
JP5345792B2 (ja) 2008-02-19 2013-11-20 テイ・エス テック株式会社 車両用格納シート
JP5331648B2 (ja) 2009-10-22 2013-10-30 株式会社日立製作所 微粉炭ボイラの改造方法

Also Published As

Publication number Publication date
CN101170995B (zh) 2013-01-16
NO20075136L (no) 2007-12-07
JP2008538105A (ja) 2008-10-09
US20060222696A1 (en) 2006-10-05
NZ561569A (en) 2011-03-31
CA2600446A1 (en) 2006-09-21
WO2006099169A3 (en) 2007-02-22
RU2007137492A (ru) 2009-04-20
EP1863448A2 (en) 2007-12-12
EP1863448B1 (en) 2014-11-26
HUE024290T2 (en) 2016-01-28
RU2454229C2 (ru) 2012-06-27
DK1863448T3 (en) 2015-02-16
AU2006223329A1 (en) 2006-09-21
ZA200708600B (en) 2009-01-28
SI1863448T1 (sl) 2015-03-31
CN101170995A (zh) 2008-04-30
KR101352490B1 (ko) 2014-02-04
PL1863448T3 (pl) 2015-05-29
HK1111625A1 (en) 2008-08-15
US20140363491A1 (en) 2014-12-11
MX2007010996A (es) 2007-11-07
US8758810B2 (en) 2014-06-24
WO2006099169A2 (en) 2006-09-21
ES2529453T3 (es) 2015-02-20
PT1863448E (pt) 2015-02-10
KR20080002819A (ko) 2008-01-04
BRPI0608297A2 (pt) 2009-12-08
AU2006223329B2 (en) 2011-11-17
JP2006248978A (ja) 2006-09-21
US7829113B2 (en) 2010-11-09
US20110081404A1 (en) 2011-04-07
JP5438317B2 (ja) 2014-03-12

Similar Documents

Publication Publication Date Title
CY1116075T1 (el) Νεες συνθεσεις λιποσωματων
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
CY1121858T1 (el) Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτες και μεθοδοι χρησης αυτων
CY1120994T1 (el) Καινοτομες συνθεσεις διαλυματος που περιεχουν κυτταρικο παραγοντα και χρηση αυτων για τη θεραπεια τραυματων
CY1111797T1 (el) Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
CY1120429T1 (el) Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
CY1118661T1 (el) Φαρμακευτικη συνθεση, φαρμακευτικη δοσολογικη μορφη, διαδικασια για την παρασκευη τους, μεθοδοι για αντιμετωπιση και χρησεις αυτων
ATE472551T1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
CY1119209T1 (el) Αναστολεις κινασης τυροσινης bruton
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
CY1117326T1 (el) Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson
NO20026255L (no) Polymere micellesammensetninger
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
EA201170036A1 (ru) Соединения боронатного эфира и его фармацевтические составы
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
TW200616640A (en) Novel pharmaceutical formulations of active principles
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
CY1115082T1 (el) Υποκατεστημενα παραγωγα 1,3-διφαινυλπροπανιου, παρασκευες και χρησεις αυτων
CY1111541T1 (el) Αγωνιστες β-2 αδρενοϋποδοχεα για την αγωγη παθησεων συνδετικου ιστου του δερματος
CY1109120T1 (el) Φαρμακευτικη συνθεση βινφλουνινης που προοριζεται για παρεντερικη χορηγηση, μεθοδος παρασκευης και χρησης
WO2008030818A3 (en) Novel liposome compositions
GT200500191A (es) Derivados de pirido - pirimidina, su preparacion, su aplicacion en terapeutica
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
PA8624401A1 (es) Procesos para la preparacion de haluros de aril- y heteroaril-alquilsulfonilo